VBLT News and Press, Vascular Biogenics Ltd. From 11/02/20

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

VBL Therapeutics (VBLT) has announced that the European Patent Office has granted patent (no. 3328401) covering the company's investigational anti-MOSPD2 (motile sperm domain-containing protein 2) monoclonal antibodies to treat a wide range of cancers, including solid tumo...

TEL AVIV, Israel, Oct. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent # 3328401 , which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology condit...

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of t...

VBL Therapeutics (VBLT) has announced that the European Patent Office has granted patent (no. 3328408) covering the company's investigational anti-MOSPD2 (motile sperm domain-containing protein 2) monoclonal antibodies to treat inflammatory and autoimmune conditions. The p...

TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent # 3328408 , which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory co...

TEL AVIV, Israel, Sept. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer,...

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executiv...

VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics ( VBLT ) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for...

TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020. ...